瑞德西韋抗新冠病毒嗎?
印象中吉利公司生產的尚在研發階段的原本目標為抗Ebola 病毒的瑞德西韋(Remdesivir)也能抗新冠病毒似乎早就
在談瑞德西韋之前先來看一下新冠肺炎病毒的生命周期及人工抑製阻
瑞得西韋是做為抗Ebola病毒而研發合成的。第一篇科學論文發表於
篩選藥物時的體外試管實驗是檢測抑製Ebola 病毒RNA-dependent RNA Polymerase (RdRp)複製合成病毒RNA的活性。瑞得西韋並不直接抑製
瑞得西韋抑製病毒RNA複製的特異性取決於病毒RdRp酶的蛋白
當然目前當務之急是搞清楚瑞得西韋 是否對新冠肺炎(或是對部分
"Expectations for the data in severe patients are modest, with the Jefferies analysts saying benefits in the 30% to 40% range are unlikely. That makes the May data on patients with moderate symptoms, a population that may be more responsive to remdesivir, perhaps the key determinants for the fate of the drug. Gilead has told investors not to base the company's future around the drug, but shares in the Big Biotech still jumped nearly 3% Monday morning.”
- FierceBiotech by Nick Paul Taylor
參考文獻:
http://news.creaders.net/
SwiperTheFox: 新冠病毒老藥新用臨床實驗 (2020-03-02) https://blog.wenxuecity.com/
Diegel, D., et al “Discovery and synthesis of a phosphoramide prodrug of a … (GS-5734) for the treatment of Ebola and emerging viruses” J. Medicinal Chemistry 2017, 60, 1648-1661
Gordon, C.J., et all “The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus” JBC, 2020 Feb 24. https://www.jbc.org/cgi/doi/
Amirian, E. S & levy, J. K “Current knowledge about antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses” One Health 9 (2020) 100128 https://doi.org/10.1016/j.
Ju J., …, Russo, J.J “Nucleotide analogues as Inhibitors of Viral Polymerases”, 2020 bioRxiv preprint: https://doi.org/10.1101/2020.
FierchBiotech: “New Gilead remdesivir COVID-19 data show up old problems with limited data” by Nick paul Taylor https://www.fiercebiotech.com/
更多我的博客文章>>>